By Martins Ifijeh
The National Institute of Allergy and Infectious Disease (NIAID) has said a United States biotech firm, Moderna, has developed an experimental vaccine against Coronavirus (COVID-19), which will be ready for first clinical trial in April.
In a statement by the Director, NIAID, Anthony Fauci, yesterday, the agency said the vaccine had been shipped to researchers just six weeks after it started working on the immunisation.
Fauci said the first batch of the COVID-19 vaccine called mRNA-1273, would be used in a planned phase 1 study in the US, which typically involves testing a vaccine on a small number of healthy humans.
He said the clinical trial could start by the end of April, and that this represents the first step in potentially making a vaccine available for use.
The Wall Street Journal, which was first to report the development, said that two doses of the vaccine would be tested on volunteers to see if it produces an immune response that protects against the virus.
Fauci told CNN that 45 people would participate in the trial.
“Even if the clinical trial is successful, further testing and regulatory approvals would be needed before the vaccine could be deployed widely,” he said.
Health officials and pharmaceutical companies around the world are working at a breakneck pace to identify treatments or a vaccine to help fight the coronavirus, which has infected more than 80,000 people around the world, and killed over 2800 persons.
Fauci previously told CNN that researchers could expedite the approval process for a vaccine following a successful Phase 1 trial in an attempt to halt the spread of the virus.
But even when proceeding at an “emergency speed,” a vaccine would not be available for use for at least a year or 18 months, according to him.
Moderna is not the only drug company hoping to find an immunization for the virus.
Pharma giants, Johnson & Johnson and GlaxoSmithKline are working on vaccines, as are government scientists including some at NIAID.
While the experimental vaccine developed by Moderna remains unproven, the speed at which it was created represents a breakthrough. According to Moderna, the vaccine was developed within 42 days of the company obtaining genetic information on Coronavirus.
By comparison, it took researchers about 20 months to start human tests of the vaccine for SARS, an older Coronavirus, according to a journal paper written by Fauci.
